Receive E-mail Alerts

Keyword Search

2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Date Title   11/11/08 ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference 11/10/08 ImmunoGen, Inc. Appoints James J. O'Leary, MD, as Vice President and Chief Medical Officer 10/27/08 ImmunoGen, Inc. Earns $4 Million Milestone Payment with sanofi-aventis' Initiation of a Phase II Trial with AVE1642 10/27/08 ImmunoGen, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 10/23/08 ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual BioInvestor Forum 10/21/08 ImmunoGen, Inc. Announces Bayer HealthCare Has Licensed Rights to TAP Technology for a Solid Tumor Target 10/20/08 ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2009 Financial Results 10/14/08 ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium 09/30/08 ImmunoGen, Inc. Announces CEO Succession Plan 09/29/08 ImmunoGen, Inc. to Present at Upcoming Investor Conferences 08/27/08 ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008 08/12/08 ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology 08/07/08 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results 07/31/08 ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2008 Financial Results 07/31/08 ImmunoGen, Inc. Announces Senior Management Promotions 07/07/08 ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing 06/23/08 ImmunoGen, Inc. Raises $25.0 Million in Registered Direct Offering of Common Stock 06/03/08 ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO 06/01/08 ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642 05/23/08 ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting 05/12/08 ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual JMP Securities Research Conference 05/01/08 ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 04/24/08 ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2008 Financial Results 04/08/08 ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research 2008 Annual Meeting 02/04/08 ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2008 02/01/08 ImmunoGen, Inc. Earns Milestone with IND Filing for BIIB015 01/31/08 ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 01/24/08 ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2008 Financial Results 01/03/08 ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds 12/27/07 ImmunoGen, Inc. Announces Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference 12/09/07 ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE9633 12/08/07 ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting with Targeted Anticancer Compounds IMGN901 (HuN901-DM1) and AVE1642 12/06/07 ImmunoGen, Inc. Announces Webcast of Panel Session at the 2007 RBC Capital Markets Healthcare Conference 11/29/07 ImmunoGen, Inc. to Host Conference Call to Review Clinical Findings Reported at ASH 11/28/07 ImmunoGen, Inc. Announces Webcast of Presentation at the BMO Capital Markets Healthcare Conference 11/27/07 ImmunoGen, Inc. Hires John Tagliamonte as Vice President, Business Development 11/26/07 ImmunoGen, Inc. Announces Presentations on Clinical-Stage Compounds at ASH Annual Meeting 11/21/07 ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference 11/19/07 ImmunoGen, Inc. Announces Addition of Richard Wallace to its Board of Directors 11/01/07 ImmunoGen, Inc. Reports First Quarter Fiscal Year 2008 Financial Results 10/25/07 ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2008 Financial Results 10/24/07 ImmunoGen, Inc. Reports New Clinical and Preclinical Data at AACR-NCI-EORTC 10/17/07 ImmunoGen, Inc. Earns Milestone with Start of SAR3419 Clinical Testing 10/04/07 ImmunoGen, Inc. To Present at the BIO InvestorForum 2007 10/03/07 ImmunoGen, Inc. Hires Craig Barrows as Vice President, General Counsel and Secretary 09/20/07 ImmunoGen, Inc. To Present at the UBS 2007 Global Life Sciences Conference 08/09/07 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 08/01/07 ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4 07/31/07 ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing 07/26/07 ImmunoGen, Inc. Announces Departure of Pauline Jen Ryan 07/10/07 ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on August 9 06/07/07 ImmunoGen, Inc. to Present at Needham & Company, LLC's Sixth Annual Biotechnology and Medical Technology Conference 06/03/07 ImmunoGen, Inc. Announces Clinical Data Reported at ASCO 05/24/07 ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO 05/17/07 ImmunoGen, Inc. Announces Resignation of Howard Pien from its Board of Directors 05/03/07 ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2007 Financial Results 04/27/07 ImmunoGen, Inc. Announces Addition of Stephen C. McCluski to its Board of Directors 04/26/07 ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2007 Financial Results 03/06/07 ImmunoGen, Inc. Announces Departure of Walter Blattler 03/06/07 ImmunoGen, Inc. To Present at the Cowen and Company 27th Annual Health Care Conference 02/22/07 ImmunoGen, Inc. Announces Webcast of Presentation at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference 02/06/07 ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2007 02/01/07 ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2007 Financial Results 01/31/07 ImmunoGen, Inc. Announces Addition of Howard Pien to its Board of Directors 01/25/07 ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2007 Financial Results 12/26/06 ImmunoGen, Inc. Announces that sanofi-aventis Has Entered into an Option Agreement for Expanded Access to the Company's TAP Technology 12/15/06 ImmunoGen, Inc. Announces Presentation of First Clinical Data for Genentech's Trastuzumab-MCC-DM1 12/11/06 ImmunoGen, Inc. Announces Presentation at ASH of Encouraging Findings with HuN901-DM1 for the Treatment of Multiple Myeloma 12/06/06 ImmunoGen, Inc. Announces Webcast of Panel Session at the 2006 RBC Capital Markets Healthcare Conference 11/21/06 ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets Third Annual Life Sciences Conference 11/10/06 ImmunoGen, Inc. Announces Presentation of HuN901-DM1 Clinical Data At EORTC-NCI-AACR Conference Showing Compound is Well Tolerated and Demonstrates Anticancer Activity 11/08/06 ImmunoGen, Inc. Announces Presentation of HuC242-DM4 Clinical Data at EORTC-NCI-AACR Conference 11/02/06 ImmunoGen, Inc. Reports First Quarter Fiscal Year 2007 Financial Results 11/01/06 ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen & Co. 7th Annual Global Health Care Conference 10/26/06 ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2007 Financial Results 10/18/06 sanofi-aventis Licenses Broader Access to ImmunoGen's Antibody Humanization Technology 10/12/06 ImmunoGen, Inc. Announces Webcast of its Presentation at the BIO Investor Forum 2006 10/04/06 ImmunoGen Announces Initiation of Clinical Testing of AVE1642 Anticancer Compound in Collaboration with sanofi-aventis 08/31/06 ImmunoGen, Inc. Announces that sanofi-aventis Has Extended the Term of its Research Collaboration with the Company; ImmunoGen Also Gains More Flexibility to Expand Product Pipeline 08/10/06 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2006 Financial Results; Company Provides Business Update 08/03/06 ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2006 Financial Results 07/11/06 ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics; ImmunoGen Has Opt-In Rights on Resulting Compounds 06/08/06 ImmunoGen, Inc. to Present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference 05/04/06 ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2006 Financial Results; Company Provides Business Update 05/04/06 ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech; Companies Also Amend 2000 Agreement for TAP Compounds Targeting HER2, Potentially Providing Increased Royalties and Milestones to ImmunoGen 04/27/06 ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2006 Financial Results 04/01/06 ImmunoGen, Inc. Announces Eight Posters to be Presented at AACR on its TAP Technology and on Compounds in Development 03/30/06 ImmunoGen, Inc. Announces Extension of Technology Access Agreement by Millennium Pharmaceuticals, Inc. 03/02/06 ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen & Co. 26th Annual Health Care Conference 02/07/06 ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2006 02/02/06 ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2006 Financial Results; Company Provides Business Update 01/31/06 ImmunoGen, Inc. Announces Achievement of Milestone in Collaboration with Genentech; Trastuzumab-DM1 IND Becomes Effective, Triggering $2 Million Payment to ImmunoGen 01/26/06 ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2006 Financial Results 12/13/05 ImmunoGen, Inc. Announces Genentech Has Taken Fourth License to Use ImmunoGen's TAP Technology to Develop Novel Anticancer Therapeutics 11/16/05 ImmunoGen, Inc. Announces Presentation of HuN901-DM1 Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 11/14/05 ImmunoGen, Inc. Announces Clinical and Preclinical Findings with TAP Compounds to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 11/03/05 ImmunoGen, Inc. Reports First Quarter Fiscal Year 2006 Financial Results 09/07/05 ImmunoGen, Inc. Initiates Clinical Testing of HuN901-DM1 for Treatment of Multiple Myeloma; Study Expands HuN901-DM1 Clinical Development Program 08/31/05 ImmunoGen, Inc. Announces that the sanofi-aventis Group Has Extended its Research Collaboration with the Company; Extension of Research Collaboration Begins September 2006 and Provides ImmunoGen with Additional Committed Funding 08/11/05 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2005 Financial Results; Company Provides Business Update 07/26/05 ImmunoGen, Inc. Announces Genentech Has Licensed Rights to Use ImmunoGen's TAP Technology with Therapeutic Antibodies to an Additional Target 06/24/05 ImmunoGen, Inc. Announces Initiation of Clinical Testing of its HuC242-DM4 Anticancer Compound; Company's Second Wholly-Owned TAP Compound Advances into Clinical Testing 06/09/05 ImmunoGen, Inc. Announces Addition of Nicole Onetto, MD, to the Board of Directors 05/17/05 ImmunoGen, Inc. Reports Initial Phase II Findings with its HuN901-DM1 Anticancer Compound in the Treatment of Small-Cell Lung Cancer; Company's Lead TAP Compound Demonstrates Objective Evidence of Anticancer Activity 05/09/05 ImmunoGen, Inc. Announces Appointment of Daniel M. Junius as Chief Financial Officer 05/05/05 ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2005 Financial Results 05/03/05 ImmunoGen, Inc. Announces Genentech's Renewal of Technology Access Agreement 04/28/05 ImmunoGen, Inc. Announces Genentech Has Licensed Rights to Use ImmunoGen's TAP Technology with Therapeutic Antibodies to a Second Target 04/19/05 ImmunoGen, Inc. Announces Data Reported at AACR on AVE9633 Anticancer Compound 04/17/05 ImmunoGen, Inc. Reports Data at AACR on the Company's HuC242-DM4 Anticancer Compound 03/31/05 ImmunoGen, Inc. Files IND for its HuC242-DM4 Targeted Anticancer Compound 03/17/05 ImmunoGen Announces Achievement of Milestone in Collaboration with Sanofi-Aventis 02/09/05 ImmunoGen, Inc. Provides Update on Collaboration with Boehringer Ingelheim 02/03/05 ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2005 Financial Results; Company Provides Business Update 01/07/05 ImmunoGen, Inc. Announces Departure of Chief Financial Officer 12/28/04 ImmunoGen, Inc. Announces that Centocor Has Licensed Certain Rights to ImmunoGen's Tumor-Activated Prodrug Technology 11/04/04 ImmunoGen, Inc. Reports First Quarter Fiscal Year 2005 Financial Results; Company Provides Business Update 10/25/04 ImmunoGen, Inc. Appoints Christopher U. Missling as Chief Financial Officer 10/06/04 Biogen Idec and ImmunoGen, Inc. to Collaborate on Development of Novel Anticancer Compound 08/12/04 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2004 Financial Results; Revenue From Partners Increased Substantially Over 2003 Levels 07/08/04 ImmunoGen, Inc. Announces Publication of Preclinical Data on the Anticancer Activity of huN901-DM1 in Multiple Myeloma 07/06/04 ImmunoGen, Inc. Appoints Dr. Robert J. Fram as Vice President, Clinical Development 06/22/04 ImmunoGen, Inc. Announces Addition to its Board of Directors 05/27/04 ImmunoGen, Inc. Announces Placement of Common Stock by Selling Stockholder 05/17/04 ImmunoGen, Inc. Announces Offering of its Common Stock by Shire BioChem Inc. 05/13/04 ImmunoGen, Inc. Reports Fiscal Year 2004 Third Quarter Financial Results; Company Provides Business Update 02/12/04 ImmunoGen, Inc. Reports Fiscal Year 2004 Second Quarter Financial Results; Company Provides Business Update 01/08/04 ImmunoGen, Inc. to Advance its Lead Product Candidates Cantuzumab Mertansine and huN901-DM1 into its Own Proof-of-Concept Studies 11/24/03 ImmunoGen, Inc. Announces Change in Chief Financial Officer Position 11/06/03 ImmunoGen, Inc. Reports First Quarter 2004 Financial Results; Company Provides Business Update 08/07/03 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2003 Financial Results 07/31/03 ImmunoGen, Inc. and Aventis Sign Collaboration Agreement to Discover, Develop, and Commercialize Novel Anticancer Therapeutics 05/08/03 ImmunoGen, Inc. Reports Third Quarter 2003 Results; Company Provides Business Update 02/06/03 ImmunoGen, Inc. Reports Second Quarter 2003 Results; Company Provides Business Update 01/24/03 ImmunoGen, Inc. Regains Development and Commercialization Rights for Cantuzumab Mertansine 01/15/03 ImmunoGen, Inc. Announces Publication of Cantuzumab Mertansine Phase I Study in the Journal of Clinical Oncology 12/04/02 ImmunoGen, Inc. Announces Start of Phase II Study with huN901-DM1 in Patients With Relapsed Small-Cell Lung Cancer 11/22/02 ImmunoGen, Inc. and British Biotech plc Announce Completion of huN901-DM1 Phase I Study 11/21/02 ImmunoGen Announces Achievement of Milestone in Collaboration with Millennium 11/07/02 ImmunoGen, Inc. Reports First Quarter 2003 Results 10/15/02 Boehringer Ingelheim and ImmunoGen Achieve Milestone in Development Of Novel Anti-Cancer Agent 08/27/02 ImmunoGen, Inc. Announces Share Repurchase Program 08/08/02 ImmunoGen, Inc. Reports Fiscal Year 2002 Results 08/08/02 ImmunoGen, Inc. and British Biotech Announce Initiation of Second Phase I Study of huN901-DM1/BB-10901 06/24/02 ImmunoGen, Inc. Provides Update on Relationship with GlaxoSmithKline and Also on the Status of Trastuzumab-DM1 06/12/02 ImmunoGen, Inc. Taxane Derivatives Show Greater Potency Than Taxol(R) Against Both Taxane-Responsive and Multi-Drug-Resistant Cancer Cell Lines 05/21/02 ImmunoGen, Inc. Announces Presentation of Data on Cantuzumab Mertansine at the Annual Meeting of the American Society of Clinical Oncology 05/20/02 ImmunoGen, Inc. and British Biotech plc Announce Presentation of Data from Ongoing Phase I/II Clinical Study of huN901-DM1/BB-10901 at the 2002 Meeting of the American Society of Clinical Oncology 05/09/02 ImmunoGen, Inc. Reports Third-Quarter Results 02/20/02 ImmunoGen and Millennium Sign Exclusive Product License 02/07/02 ImmunoGen, Inc. Reports Second-Quarter Results 01/23/02 ImmunoGen, Inc. Receives Patent on Taxane Compounds 01/04/02 ImmunoGen, Inc. Receives Patent on Production of DM1 11/28/01 Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement 11/08/01 ImmunoGen, Inc. Reports First-Quarter Results 11/01/01 ImmunoGen's Partner Genentech Presents Favorable Preclinical Results of Trastuzumab-DM1 at AACR-NCI-EORTC Meeting 11/01/01 ImmunoGen Announces Favorable Preliminary Phase I/II Data on huC242-DM1/SB-408075 10/30/01 ImmunoGen Introduces New Taxane-Based Tumor-Activated Prodrug Platform 10/22/01 ImmunoGen Reports Anti-Tumor Activity For New Tumor-Activated Prodrug For Acute Myelogenous Leukemia 08/16/01 ImmunoGen, Inc. Reports Financial Results for Fiscal Year 2001 06/28/01 ImmunoGen & BioInvent Sign Antibody Manufacturing Agreement 06/21/01 MorphoSys and ImmunoGen Expand Existing Collaboration License of HuCAL(R) For Target Research 05/29/01 British Biotech and ImmunoGen Begin Patient Enrollment for the Phase I/II Trial of BB-10901/huN901-DM1 in Small Cell Lung Cancer 05/14/01 ImmunoGen Reports Promising Results from Phase I/II Human Clinical Study with Product Candidate for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers 05/10/01 ImmunoGen, Inc. Reports Third Quarter Results, Beating Expectations by $0.01 05/08/01 ImmunoGen Begins Enrollment in a Third Phase I/II Human Clinical Study with Lead Product for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers 03/29/01 ImmunoGen and Raven Biotechnologies Announce Target and Antibody Discovery Collaboration in Ovarian Cancer 03/05/01 Millennium and ImmunoGen Form Multi-Product Antibody Collaboration 03/05/01 ImmunoGen Appoints New Chief Financial Officer 02/08/01 ImmunoGen, Inc. Reports Second Quarter Results 02/01/01 ImmunoGen Comments on Recent SEC Lawsuit 01/25/01 ImmunoGen and Avalon Enter Genomics-Based Collaboration